-logo-1200x675.png?v=20220915161652&w=240&h=240&zc=2){kind=logo}
The Goldman Sachs Group Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price objective hoisted by The Goldman Sachs Group from $13.00 to $15.00 in a research note released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other brokerages have also recently issued reports on ARQT. Mizuho raised their […]
Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price objective hoisted by The Goldman Sachs Group from $13.00 to $15.00 in a research note released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other brokerages have also recently issued reports on ARQT. Mizuho raised their […]
